China Biologic Products (CBPO) 98.59 $CBPO
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 14.05 (+0.12), FOMX: 10.46 (-0.44), PVCT: 0.92 (unch), JNJ: 101.08 (+0.62), DERM: 14.96 (-0.14), ANAC: 64.49 (-2.10), XNCR: 14.73 (+0.22), REGN: 480.09 (+0.01), AQXP: 7.77 (-0.03), BMY: 65.80 (-0.20), GSK: 46.59 (+0.28), VRX.TO: 255.98 (+1.76), CBPO: 98.59 (-0.35), MRK: 57.60 (+0.09), CCXI: 7.62 (-0.27), CLTX: 0.76 (+0.01), CELGZ: 2.76 (-0.12), NVS: 104.28 (-1.22)
China Biologic Receives Approval to Purchase Raw Materials
PR Newswire - Thu Apr 16, 7:00AM CDT
China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its subsidiary, Guizhou Taibang Biological Products Co., Ltd. ("Guizhou Taibang" , has received a one-time special approval from the China Food and Drug Administration (the "CFDA" to purchase up to approximately 143 tonnes of source plasma and plasma pastes from Xinjiang Deyuan Bioengineering Co., Ltd. ("Xinjiang Deyuan" for a total consideration of up to approximately RMB139 million (approximately US$22.4 million) pursuant to certain agreements entered into between Guizhou Taibang and Xinjiang Deyuan. Source plasma and plasma pastes are raw materials for producing human albumin and intravenous immunoglobulin ("IVIG" products.
CBPO: 98.59 (-0.35)
Bespoke's Trading Range Screen: China ADRs
Bespoke Investment Group - at Seeking Alpha - Wed Apr 15, 1:30AM CDT
China's stock market has been surging lately, and investors in the US have been riding the wave with a number of Chinese ADRs. Below we've run the 30 largest Chinese ADRs through our trading range screen. For each stock, the dot represents where it's...
SINA: 38.54 (+1.19), VIPS: 28.95 (-0.92), YY: 63.87 (+0.95), YOKU: 17.03 (+0.12), QIHU: 62.62 (+0.06), MPEL: 21.99 (+0.07), WX: 39.62 (+0.26), CTRP: 65.57 (-0.05), WUBA: 79.42 (+1.16), NTES: 122.19 (+3.26), JMEI: 22.10 (+0.30), EDU: 26.52 (-0.17), CMCM: 24.11 (+0.13), MOMO: 12.41 (+1.02), MR: 30.95 (+0.07), XRS: 36.24 (-0.64), ATHM: 53.31 (+0.92), BITA: 61.63 (+2.86), NORD: 23.83 (-0.95), CBPO: 98.59 (-0.35), JOBS: 36.02 (-0.17), QUNR: 48.02 (-0.14), WB: 17.20 (+1.31), BIDU: 216.90 (+4.62), GAME: 6.85 (-0.01), SOHU: 67.54 (+1.99), SFUN: 8.04 (-0.52), JD: 34.72 (+1.06), SSW: 19.60 (-0.02), BABA: 84.57 (+2.29)
Research and Markets: Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report 2015-2020 Featuring Baxter, Beijing Tiantan Biological Products, Bharat Serums and Vaccines, Biotest AG & China Biologic Products
Business Wire - Thu Mar 19, 9:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vx68j8/intravenous) has announced the addition of the "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report to their offering.
CBPO: 98.59 (-0.35)
Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report 2015-2020 Featuring Baxter, Beijing Tiantan Biological Products, Bharat Serums and Vaccines, Biotest AG & China Biologic Products
M2 - Thu Mar 19, 7:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nhmrwk/intravenous) has announced the addition of the "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million and in Kilograms. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as: - Baxter International, Inc. - Beijing Tiantan Biological Products Co., Ltd. - Bharat Serums and Vaccines Limited - Biotest AG - China Biologic Products, Inc.ogics Key Topics Covered: 1. INDUSTRY OVERVIEW 2. MARKET TRENDS 3. PLASMA PROTEINS - AN OVERVIEW 4. THERAPY OVERVIEW 5. REGULATORY APPROVALS 6. PRODUCT INNOVATIONS/INTRODUCTIONS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 25 (including Divisions/Subsidiaries - 30) - The United States (10) - Japan (1) - Europe (7) - - France (1) - - Germany (1) - - The United Kingdom (1) - - Italy (1) - - Spain (1) - - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (10) - Latin America (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/nh...ntravenous
CBPO: 98.59 (-0.35), BAX: 71.14 (-0.37)
China Biologic Products' (CBPO) CEO David Gao on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Mar 06, 5:56PM CST
CBPO: 98.59 (-0.35)
China Biologic Products posts 4Q profit
Automated Insights - Wed Mar 04, 5:10PM CST
TAI`AN CITY SHANDONG, China (AP) _ China Biologic Products Inc. (CBPO) on Wednesday reported fourth-quarter profit of $12.9 million.
CBPO: 98.59 (-0.35)
China Biologic Products beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 4:05PM CST
CBPO: 98.59 (-0.35)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 35.23 (+0.22), CASM: 1.30 (unch), AMRN: 2.33 (-0.10), XON: 44.10 (-0.91), OSIR: 16.33 (-0.26), CPIX: 6.97 (+0.02), AMED: 26.82 (unch), CTIC: 1.96 (+0.01), INSY: 62.42 (-1.90), ECYT: 6.17 (-0.13), CMRX: 39.48 (-0.53), KYTH: 50.44 (-0.54), TRIB: 17.18 (+0.02), GALE: 1.45 (+0.02), ARNA: 4.49 (+0.05), XLRN: 33.29 (-0.95), ACRX: 4.58 (-0.16), ENDP: 93.27 (-0.81), DPLO: 36.71 (+0.46), SLXP: 172.96 (+0.15), PPHM: 1.38 (-0.05), MYL: 76.06 (+2.37), CBPO: 98.59 (-0.35), RGEN: 34.75 (-0.25), HALO: 16.86 (-0.08), ALIM: 4.94 (-0.07), ACHN: 10.06 (+0.06), GERN: 4.30 (-0.03), DARA: 0.81 (+0.04), SCMP: 21.09 (-0.31), ICPT: 283.20 (-2.22), CDXS: 4.71 (-0.30), PCRX: 85.07 (+0.80), PBYI: 222.10 (-6.35), FOLD: 12.25 (-0.05)
China Biologic Products CBPO) Falls: Stock Goes Down 6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 25, 7:49AM CST
China Biologic Products saw a big move last session, as the company’s shares fell nearly 6% on the day.
CBPO: 98.59 (-0.35), CBM: 42.97 (+0.37)
China Biologic Products Q4 2014 Earnings: Primed For A Sell-Off?
Trevor Lowenthal - at Seeking Alpha - Mon Feb 23, 8:50AM CST
CBPO: 98.59 (-0.35)
Nasdaq stocks posting largest percentage increases
AP - Fri Feb 20, 12:37PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
TILE: 20.26 (-0.09), PATK: 60.86 (+0.04), DISCB: 33.42 (-0.27), DISCA: 32.71 (-0.93), FUNC: 8.53 (+0.03), IKNX: 14.75 (unch), CBPO: 98.59 (-0.35), EGLT: 10.26 (+0.05), DISCK: 31.02 (-0.78), ASMB: 15.45 (-1.54), AMOT: 41.04 (+0.49), ATRO: 74.24 (-1.72), ARIA: 9.71 (+0.10), THRX: 17.92 (+0.46), UNTD: 17.47 (-0.16), SZMK: 7.64 (-0.03)
My Top Biotechnology Stocks For 2015
Stan Stafford - at Seeking Alpha - Thu Feb 19, 8:49AM CST
MDVN: 131.01 (-1.50), CBPO: 98.59 (-0.35), BIIB: 401.71 (-28.57), INSY: 62.42 (-1.90), MYGN: 33.59 (-0.77), PCYC: 256.59 (-0.51), GILD: 103.69 (-1.52), UTHR: 186.69 (-1.87), ALXN: 180.08 (-4.50), LGND: 89.75 (+0.83), ACOR: 33.12 (-0.38), REGN: 480.09 (+0.01), PDLI: 7.02 (-0.09)
China Biologic Products (CBPO) Catches Eye: Stock Up 6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 7:30AM CST
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise almost 6% on the day.
CBPO: 98.59 (-0.35), AFFX: 12.44 (-0.16)
China Biologic Products to Report Fourth Quarter and Fiscal Year 2014 Financial Results
PR Newswire - Tue Feb 17, 7:30AM CST
China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company" , a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release fourth quarter and fiscal year 2014 financial results on, March 4, 2015, after the market closes.
CBPO: 98.59 (-0.35)
A Look at the Latest Occurrences in the Biotechnology Sector: Special Research on China Biologic Products, Compugen, Curis, CytRx, and DBV Technologies
PR Newswire - Mon Feb 16, 7:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
CBPO: 98.59 (-0.35), CRIS: 2.96 (-0.01), DBVT: 26.29 (+0.41), CYTR: 5.13 (-0.13), CGEN: 7.00 (-0.09)
Your Weekly Review: Growth Stocks Show Signs Of Life
at Investor's Business Daily - Thu Feb 12, 5:12PM CST
The good news for growth investors is that the market is back in a confirmed uptrend. Even better news is that this week's Your Weekly Review screen shows plenty of compelling candidates. Despite nagging distribution days in the S&P 500 and Nasdaq,...
CBPO: 98.59 (-0.35), ZTS: 47.91 (+0.86), SSNC: 63.62 (-1.08), AAP: 148.61 (+1.92), ORLY: 229.35 (+1.04), MIDD: 103.17 (-0.52), SPR: 51.88 (-0.26), MPWR: 49.96 (-3.55), DATA: 102.40 (+0.20)
Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea
at Investor's Business Daily - Tue Feb 10, 10:01AM CST
Regeneron Pharmaceuticals (REGN) reported weaker-than-expected fourth-quarter earnings Tuesday morning, but the large-cap biotech topped sales views and offered an upbeat outlook for its blockbuster Eylea eye drug, which generates well more than half...
CBPO: 98.59 (-0.35), BIIB: 401.71 (-28.57), INSY: 62.42 (-1.90), PCYC: 256.59 (-0.51), BMRN: 120.28 (-2.67), AMGN: 167.91 (-1.26), SNY: 51.75 (-0.01), REGN: 480.09 (+0.01), CELG: 118.71 (+2.62)
Update: China Biologic Products Adopts Stockholder Plan To Avoid Hostile Takeover
Trevor Lowenthal - at Seeking Alpha - Fri Jan 09, 12:14PM CST
CBPO: 98.59 (-0.35)
Weekly Review Shows Five Industries Gain In December
at Investor's Business Daily - Thu Jan 08, 5:06PM CST
A step back sometimes provides perspective. In this case, a comparison of the current Your Weekly Review list to that of the first week of December shows some revealing changes. Pharmaceutical stocks came under clear pressure during the month, with...
AMBA: 72.13 (-1.32), AKRX: 55.24 (-0.68), AMGN: 167.91 (-1.26), JBLU: 19.89 (+0.14), ACOR: 33.12 (-0.38), MPWR: 49.96 (-3.55), BWLD: 180.50 (+1.84), EAT: 57.59 (+0.23), FRGI: 54.90 (-4.19), LUV: 43.49 (+0.23), CBPO: 98.59 (-0.35), BIDU: 216.90 (+4.62), SWFT: 25.78 (-0.51), KNX: 31.45 (-0.14), ALXN: 180.08 (-4.50), DPZ: 113.96 (+4.73), SAIA: 42.99 (-0.10), AVGO: 119.50 (-4.57), SIMO: 30.40 (-2.75), BABA: 84.57 (+2.29)
Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 14.05 (+0.12), FOMX: 10.46 (-0.44), PVCT: 0.92 (unch), JNJ: 101.08 (+0.62), DERM: 14.96 (-0.14), ANAC: 64.49 (-2.10), XNCR: 14.73 (+0.22), REGN: 480.09 (+0.01), AQXP: 7.77 (-0.03), BMY: 65.80 (-0.20), GSK: 46.59 (+0.28), VRX.TO: 255.98 (+1.76), CBPO: 98.59 (-0.35), MRK: 57.60 (+0.09), CCXI: 7.62 (-0.27), CLTX: 0.76 (+0.01), CELGZ: 2.76 (-0.12), NVS: 104.28 (-1.22)
China Biologic Receives Approval to Purchase Raw Materials
PR Newswire - Thu Apr 16, 7:00AM CDT
China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its subsidiary, Guizhou Taibang Biological Products Co., Ltd. ("Guizhou Taibang" , has received a one-time special approval from the China Food and Drug Administration (the "CFDA" to purchase up to approximately 143 tonnes of source plasma and plasma pastes from Xinjiang Deyuan Bioengineering Co., Ltd. ("Xinjiang Deyuan" for a total consideration of up to approximately RMB139 million (approximately US$22.4 million) pursuant to certain agreements entered into between Guizhou Taibang and Xinjiang Deyuan. Source plasma and plasma pastes are raw materials for producing human albumin and intravenous immunoglobulin ("IVIG" products. CBPO: 98.59 (-0.35)
Bespoke's Trading Range Screen: China ADRs
Bespoke Investment Group - at Seeking Alpha - Wed Apr 15, 1:30AM CDT
China's stock market has been surging lately, and investors in the US have been riding the wave with a number of Chinese ADRs. Below we've run the 30 largest Chinese ADRs through our trading range screen. For each stock, the dot represents where it's...
SINA: 38.54 (+1.19), VIPS: 28.95 (-0.92), YY: 63.87 (+0.95), YOKU: 17.03 (+0.12), QIHU: 62.62 (+0.06), MPEL: 21.99 (+0.07), WX: 39.62 (+0.26), CTRP: 65.57 (-0.05), WUBA: 79.42 (+1.16), NTES: 122.19 (+3.26), JMEI: 22.10 (+0.30), EDU: 26.52 (-0.17), CMCM: 24.11 (+0.13), MOMO: 12.41 (+1.02), MR: 30.95 (+0.07), XRS: 36.24 (-0.64), ATHM: 53.31 (+0.92), BITA: 61.63 (+2.86), NORD: 23.83 (-0.95), CBPO: 98.59 (-0.35), JOBS: 36.02 (-0.17), QUNR: 48.02 (-0.14), WB: 17.20 (+1.31), BIDU: 216.90 (+4.62), GAME: 6.85 (-0.01), SOHU: 67.54 (+1.99), SFUN: 8.04 (-0.52), JD: 34.72 (+1.06), SSW: 19.60 (-0.02), BABA: 84.57 (+2.29)
Research and Markets: Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report 2015-2020 Featuring Baxter, Beijing Tiantan Biological Products, Bharat Serums and Vaccines, Biotest AG & China Biologic Products
Business Wire - Thu Mar 19, 9:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vx68j8/intravenous) has announced the addition of the "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report to their offering.
CBPO: 98.59 (-0.35)
Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report 2015-2020 Featuring Baxter, Beijing Tiantan Biological Products, Bharat Serums and Vaccines, Biotest AG & China Biologic Products
M2 - Thu Mar 19, 7:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nhmrwk/intravenous) has announced the addition of the "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million and in Kilograms. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as: - Baxter International, Inc. - Beijing Tiantan Biological Products Co., Ltd. - Bharat Serums and Vaccines Limited - Biotest AG - China Biologic Products, Inc.ogics Key Topics Covered: 1. INDUSTRY OVERVIEW 2. MARKET TRENDS 3. PLASMA PROTEINS - AN OVERVIEW 4. THERAPY OVERVIEW 5. REGULATORY APPROVALS 6. PRODUCT INNOVATIONS/INTRODUCTIONS 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 25 (including Divisions/Subsidiaries - 30) - The United States (10) - Japan (1) - Europe (7) - - France (1) - - Germany (1) - - The United Kingdom (1) - - Italy (1) - - Spain (1) - - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (10) - Latin America (1) - Middle East (1) For more information visit http://www.researchandmarkets.com/research/nh...ntravenous
CBPO: 98.59 (-0.35), BAX: 71.14 (-0.37)
China Biologic Products' (CBPO) CEO David Gao on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Mar 06, 5:56PM CST
CBPO: 98.59 (-0.35)
China Biologic Products posts 4Q profit
Automated Insights - Wed Mar 04, 5:10PM CST
TAI`AN CITY SHANDONG, China (AP) _ China Biologic Products Inc. (CBPO) on Wednesday reported fourth-quarter profit of $12.9 million.
CBPO: 98.59 (-0.35)
China Biologic Products beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 4:05PM CST
CBPO: 98.59 (-0.35)
Next Week In Biotech: Pacira PDUFA, Geron And Dendreon Report
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 27, 8:00AM CST
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
BRLI: 35.23 (+0.22), CASM: 1.30 (unch), AMRN: 2.33 (-0.10), XON: 44.10 (-0.91), OSIR: 16.33 (-0.26), CPIX: 6.97 (+0.02), AMED: 26.82 (unch), CTIC: 1.96 (+0.01), INSY: 62.42 (-1.90), ECYT: 6.17 (-0.13), CMRX: 39.48 (-0.53), KYTH: 50.44 (-0.54), TRIB: 17.18 (+0.02), GALE: 1.45 (+0.02), ARNA: 4.49 (+0.05), XLRN: 33.29 (-0.95), ACRX: 4.58 (-0.16), ENDP: 93.27 (-0.81), DPLO: 36.71 (+0.46), SLXP: 172.96 (+0.15), PPHM: 1.38 (-0.05), MYL: 76.06 (+2.37), CBPO: 98.59 (-0.35), RGEN: 34.75 (-0.25), HALO: 16.86 (-0.08), ALIM: 4.94 (-0.07), ACHN: 10.06 (+0.06), GERN: 4.30 (-0.03), DARA: 0.81 (+0.04), SCMP: 21.09 (-0.31), ICPT: 283.20 (-2.22), CDXS: 4.71 (-0.30), PCRX: 85.07 (+0.80), PBYI: 222.10 (-6.35), FOLD: 12.25 (-0.05)
China Biologic Products CBPO) Falls: Stock Goes Down 6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 25, 7:49AM CST
China Biologic Products saw a big move last session, as the company’s shares fell nearly 6% on the day.
CBPO: 98.59 (-0.35), CBM: 42.97 (+0.37)
China Biologic Products Q4 2014 Earnings: Primed For A Sell-Off?
Trevor Lowenthal - at Seeking Alpha - Mon Feb 23, 8:50AM CST
CBPO: 98.59 (-0.35)
Nasdaq stocks posting largest percentage increases
AP - Fri Feb 20, 12:37PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
TILE: 20.26 (-0.09), PATK: 60.86 (+0.04), DISCB: 33.42 (-0.27), DISCA: 32.71 (-0.93), FUNC: 8.53 (+0.03), IKNX: 14.75 (unch), CBPO: 98.59 (-0.35), EGLT: 10.26 (+0.05), DISCK: 31.02 (-0.78), ASMB: 15.45 (-1.54), AMOT: 41.04 (+0.49), ATRO: 74.24 (-1.72), ARIA: 9.71 (+0.10), THRX: 17.92 (+0.46), UNTD: 17.47 (-0.16), SZMK: 7.64 (-0.03)
My Top Biotechnology Stocks For 2015
Stan Stafford - at Seeking Alpha - Thu Feb 19, 8:49AM CST
MDVN: 131.01 (-1.50), CBPO: 98.59 (-0.35), BIIB: 401.71 (-28.57), INSY: 62.42 (-1.90), MYGN: 33.59 (-0.77), PCYC: 256.59 (-0.51), GILD: 103.69 (-1.52), UTHR: 186.69 (-1.87), ALXN: 180.08 (-4.50), LGND: 89.75 (+0.83), ACOR: 33.12 (-0.38), REGN: 480.09 (+0.01), PDLI: 7.02 (-0.09)
China Biologic Products (CBPO) Catches Eye: Stock Up 6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 7:30AM CST
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise almost 6% on the day.
CBPO: 98.59 (-0.35), AFFX: 12.44 (-0.16)
China Biologic Products to Report Fourth Quarter and Fiscal Year 2014 Financial Results
PR Newswire - Tue Feb 17, 7:30AM CST
China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"
, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release fourth quarter and fiscal year 2014 financial results on, March 4, 2015, after the market closes. CBPO: 98.59 (-0.35)
A Look at the Latest Occurrences in the Biotechnology Sector: Special Research on China Biologic Products, Compugen, Curis, CytRx, and DBV Technologies
PR Newswire - Mon Feb 16, 7:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
CBPO: 98.59 (-0.35), CRIS: 2.96 (-0.01), DBVT: 26.29 (+0.41), CYTR: 5.13 (-0.13), CGEN: 7.00 (-0.09)
Your Weekly Review: Growth Stocks Show Signs Of Life
at Investor's Business Daily - Thu Feb 12, 5:12PM CST
The good news for growth investors is that the market is back in a confirmed uptrend. Even better news is that this week's Your Weekly Review screen shows plenty of compelling candidates. Despite nagging distribution days in the S&P 500 and Nasdaq,...
CBPO: 98.59 (-0.35), ZTS: 47.91 (+0.86), SSNC: 63.62 (-1.08), AAP: 148.61 (+1.92), ORLY: 229.35 (+1.04), MIDD: 103.17 (-0.52), SPR: 51.88 (-0.26), MPWR: 49.96 (-3.55), DATA: 102.40 (+0.20)
Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea
at Investor's Business Daily - Tue Feb 10, 10:01AM CST
Regeneron Pharmaceuticals (REGN) reported weaker-than-expected fourth-quarter earnings Tuesday morning, but the large-cap biotech topped sales views and offered an upbeat outlook for its blockbuster Eylea eye drug, which generates well more than half...
CBPO: 98.59 (-0.35), BIIB: 401.71 (-28.57), INSY: 62.42 (-1.90), PCYC: 256.59 (-0.51), BMRN: 120.28 (-2.67), AMGN: 167.91 (-1.26), SNY: 51.75 (-0.01), REGN: 480.09 (+0.01), CELG: 118.71 (+2.62)
Update: China Biologic Products Adopts Stockholder Plan To Avoid Hostile Takeover
Trevor Lowenthal - at Seeking Alpha - Fri Jan 09, 12:14PM CST
CBPO: 98.59 (-0.35)
Weekly Review Shows Five Industries Gain In December
at Investor's Business Daily - Thu Jan 08, 5:06PM CST
A step back sometimes provides perspective. In this case, a comparison of the current Your Weekly Review list to that of the first week of December shows some revealing changes. Pharmaceutical stocks came under clear pressure during the month, with...
AMBA: 72.13 (-1.32), AKRX: 55.24 (-0.68), AMGN: 167.91 (-1.26), JBLU: 19.89 (+0.14), ACOR: 33.12 (-0.38), MPWR: 49.96 (-3.55), BWLD: 180.50 (+1.84), EAT: 57.59 (+0.23), FRGI: 54.90 (-4.19), LUV: 43.49 (+0.23), CBPO: 98.59 (-0.35), BIDU: 216.90 (+4.62), SWFT: 25.78 (-0.51), KNX: 31.45 (-0.14), ALXN: 180.08 (-4.50), DPZ: 113.96 (+4.73), SAIA: 42.99 (-0.10), AVGO: 119.50 (-4.57), SIMO: 30.40 (-2.75), BABA: 84.57 (+2.29)
